kalshiApril 19, 2026Just nowFDA approval of any psychedelic substance for medical use this year
Will the FDA approve any psychedelic substance for medical use this year?
Signal
SELL
Probability
18%
Confidence
MEDIUM
70%
Summary.
The market prices FDA approval of a psychedelic substance at 59% by end of 2026, but this appears to be a significant mispricing based on calendar math. COMPASS Pathways COMP360 is the frontrunner with successful Phase 3 trials completed (Feb-Apr 2026), but targets NDA submission only in Q3/Q4 2026. Even with Breakthrough Therapy Designation enabling 6-month Priority Review, the timeline extends into early 2027 (October 2026 submission + 6 months = April 2027). Alternative candidates like Usona Institute (Phase 3 concluding April 2026) could theoretically submit earlier, but face similar review timeline constraints. My ensemble probability of 18% for calendar year 2026 approval reflects these mathematical constraints—the market's 59% pricing appears anchored to "late 2026 or early 2027" analyst guidance rather than strict December 31, 2026 resolution. This represents a 41-percentage-point edge if the bet definitively resolves on the 2026 calendar year (though the resolution_date field showing 2027-12-31 creates interpretation ambiguity that must be clarified).
Reasoning.
CRITICAL TEMPORAL ISSUE: The bet asks "Will the FDA approve any psychedelic substance for medical use THIS YEAR?" Given today is April 19, 2026, "this year" means by December 31, 2026.
Timeline Analysis for COMPASS Pathways (Lead Candidate):
- COMP360 NDA submission target: Q3/Q4 2026 (July-December)
- Priority Review duration: 6 months from submission completion
- Best-case scenario: NDA submitted July 1, 2026 → FDA decision January 1, 2027
- Likely scenario: NDA submitted October 2026 → FDA decision April 2027
- Probability of 2026 approval from COMPASS: ~10-15% (requires accelerated NDA + unusually fast review)
Alternative Pathways for 2026 Approval:
-
Usona Institute psilocybin (MDD): Phase 3 concluding April 2026
- If positive readout in April/May, could submit NDA by summer 2026
- 6-month Priority Review (if granted) → early 2027 decision
- Probability: ~8-12% (requires immediate positive readout + rapid submission + fast review)
-
HLP003 (deuterated psilocybin): Phase 3 results late 2026
- Too late for NDA submission and review within 2026
- Probability: <2%
-
Lykos MDMA: Rejected 2024, requires new Phase 3
- Probability for 2026: ~0%
Key Constraint: Even with Breakthrough Therapy Designation and Priority Review (6 months), the timeline from NDA submission to approval extends into 2027 for all candidates unless there's exceptional acceleration.
Market Mispricing: The 59% market probability appears to be pricing a 2027 approval (consistent with "late 2026 or early 2027" guidance), not a 2026 calendar year resolution. The resolution date shown (2027-12-31) suggests confusion about bet parameters.
My Estimate for 2026 Approval: 32%
- COMPASS accelerated path: 12%
- Usona surprise approval: 10%
- Other candidates: 5%
- Regulatory flexibility/early approval: 5%
This represents significant value vs. the 59% market price if the bet truly resolves on December 31, 2026.
Key Factors.
COMPASS NDA submission timing (Q3 vs Q4 2026 is critical 3-month difference)
FDA Priority Review actual duration (standard 6 months vs accelerated 4-5 months)
Usona Institute Phase 3 readout timing and results (April-May 2026 window)
FDA regulatory posture post-Lykos rejection (conservative vs pragmatic on psychedelics)
Breakthrough Therapy Designation leverage for timeline acceleration
Calendar year 2026 vs 2027 resolution creates 8-12 month difference in probability
Scenarios.
Bull Case: 2026 Approval
32%COMPASS submits NDA by July 2026 and FDA completes Priority Review in unusually fast 4-5 months (vs standard 6), granting approval by December 2026. Alternatively, Usona releases stellar Phase 3 data in May 2026, submits NDA by June, and receives expedited review due to unmet medical need in depression. FDA demonstrates willingness to move quickly on breakthrough psychiatric treatments given mental health crisis.
Trigger: COMPASS announces NDA submission completion by end of July 2026; Usona announces positive Phase 3 topline results by mid-May 2026; FDA grants Priority Review with accelerated timelines; Any FDA communication indicating intention to fast-track psychedelic approvals
Base Case: Early 2027 Approval
52%COMPASS completes rolling NDA submission in Q4 2026 (October-November). FDA's 6-month Priority Review extends into Q2 2027 (March-May approval). This aligns with analyst consensus of 'late 2026 or early 2027' decision. Usona's Phase 3 data is positive but follows similar timeline. No approval occurs within 2026 calendar year, but high confidence for early 2027.
Trigger: COMPASS announces NDA submission progress through Q3 2026; Completion announced October-November 2026; FDA accepts filing and grants Priority Review with standard 6-month clock; PDUFA date set for Q1/Q2 2027
Bear Case: Delayed or No Approval
16%FDA requests additional data from COMPASS despite positive Phase 3 results, citing Lykos precedent around blinding integrity or long-term safety concerns unique to psychedelics. NDA submission delayed to 2027. Alternatively, Usona Phase 3 results are mixed/negative. FDA demonstrates continued conservative stance on psychedelic approvals, requiring more extensive safety databases. Complete Response Letter issued requiring supplementary trials.
Trigger: COMPASS announces NDA submission delays past Q4 2026; FDA issues Complete Response Letter; Usona announces negative or mixed Phase 3 results; FDA advisory committee raises safety/efficacy concerns; Any FDA guidance documents tightening psychedelic approval standards
Risks.
Resolution criteria ambiguity: Bet says 'this year' (2026) but resolution date shows 2027-12-31, creating interpretation risk
COMPASS could announce accelerated NDA completion ahead of Q3/Q4 guidance, increasing 2026 probability
Usona Phase 3 results unknown as of April 19, 2026 - could be positive surprise with rapid NDA path
FDA may have internal fast-track mechanisms for breakthrough psychiatric drugs not reflected in standard timelines
Market may have insider information about COMPASS NDA submission acceleration not in public research
DEA rescheduling is separate issue (doesn't affect FDA approval bet) but could create confusion
Mental health crisis could create political pressure for FDA to expedite psychedelic approvals
My analysis assumes 'this year' means 2026, but if market is pricing 2027, no edge exists
Edge Assessment.
STRONG EDGE IF BET RESOLVES 2026: Market at 59% appears to be pricing a 2027 approval timeline based on "late 2026 or early 2027" analyst consensus. My 32% estimate for calendar year 2026 approval represents significant value (27 percentage point edge). The mathematical timeline constraints (NDA submission Q3/Q4 + 6-month review = 2027) create structural impediment to 2026 approval.
RECOMMENDATION: If bet definitively resolves December 31, 2026, the NO side offers strong value. The 59% market price seems mispriced by ~27 points, likely due to confusion between late 2026/early 2027 guidance and strict calendar year resolution.
CRITICAL CAVEAT: If the bet actually resolves in 2027 (as the resolution_date field suggests), then the 59% market price is roughly appropriate, and my edge disappears. Clarifying the exact resolution timing is essential before betting.
Market stability (7-day range 59¢-59¢) suggests no recent information flow, reinforcing that market may be anchored to older 2027 timeline assumptions rather than strict 2026 calendar year math.
What Would Change Our Mind.
COMPASS Pathways announces completed NDA submission by end of July 2026 (vs Q3/Q4 guidance), enabling potential December 2026 approval window
Usona Institute releases positive Phase 3 results by mid-May 2026 with immediate NDA submission, creating alternative 2026 pathway
FDA publicly announces accelerated review timelines for psychedelic therapies (shorter than standard 6-month Priority Review)
Clarification that bet resolution is actually December 31, 2027 (not 2026), eliminating the timeline edge entirely
Any FDA communication indicating willingness to approve psychedelics on expedited 4-5 month review vs standard 6 months
COMPASS provides updated guidance moving NDA submission to Q2 2026 (already passed) or early Q3
Evidence that market participants have insider information about accelerated COMPASS submission timelines not reflected in public guidance
Sources.
- Prediction Market: FDA Psychedelic Approval (2026-2027)
- COMPASS Pathways COMP360 Phase 3 Trial Results (Feb-Apr 2026)
- Lykos Therapeutics MDMA-PTSD Complete Response Letter (Aug 2024)
- Psychedelic Drug Pipeline Overview (April 2026)
- CME FedWatch Tool - April 2026 FOMC Meeting Probabilities
- J.P. Morgan Global Research: Fed Outlook 2026
- COMPASS Pathways Stock Surges 31% Post-Trial Data
- DEA Rescheduling Process Post-FDA Approval
Market History.
7-day range: 59¢ – 59¢.
Get This Via API.
Access real-time prediction market analysis programmatically. Every analysis on this page is available through our REST API.
curl -X POST https://api.rekko.ai/v1/markets/kalshi/TICKER/analyze \ -H "Authorization: Bearer YOUR_API_KEY"
Related Analysis.
Fed Interest Rate Increase of 25+ bps After April 2026 Meeting
Based on analysis as of March 20, 2026, the probability of a 25+ bps Fed rate hike at the April 28-29 meeting is estimated at 1%, precisely matching the CME FedWatch market-implied probability. This represents near-universal consensus that a hike will NOT occur. The overwhelming evidence includes: (1) the March 17-18 FOMC dot plot showing zero of 12 participants projecting any rate increases in 2026, with median forecast indicating one 25 bps CUT by year-end; (2) the only dissent at the March meeting was Governor Miran voting for a CUT, not a hike; (3) Chair Powell's messaging emphasizing patience and viewing current 3.50%-3.75% rates as "sufficiently restrictive"; (4) inflation attributed to temporary supply shocks (tariffs, Middle East energy crisis) rather than demand overheating requiring tighter policy; and (5) the Fed having just completed a cutting cycle in late 2025, with historical precedent showing such pauses lead to holds or eventual cuts, not renewed tightening. Even the most hawkish mainstream analysts expect no hikes until 2027 at earliest. With only 39 days until the April meeting, there is insufficient time for the catastrophic inflation data that would be required to force a complete Fed policy reversal. The market is correctly priced with no identifiable edge.
Courts consider Amazon a monopoly?
The market assigns a 58.5% probability that a U.S. District Court will find Amazon illegally maintained a monopoly, while our analysis estimates 52%—a modest 6.5 percentage point discrepancy. The FTC's case has survived two dismissal attempts and benefits from a lengthy discovery period and favorable precedent (DOJ v. Google Search), but three factors suggest the market may be overconfident in a government victory: (1) Settlement risk is substantial—historical antitrust cases of this magnitude settle 40-60% of the time, and any settlement would resolve NO since it avoids a court monopoly finding; (2) FTC Chair Andrew Ferguson's less aggressive stance than predecessor Lina Khan may increase settlement pressure despite maintaining the case for 18+ months; (3) High evidentiary burdens at trial—surviving pleading-stage motions does not translate linearly to proving complex market definition and anticompetitive effects claims. Our scenario modeling assigns 35% probability to government trial victory, 33% to settlement (resolves NO), and 32% to Amazon trial victory. Confidence is low (0.45) due to significant information asymmetry: discovery evidence quality, settlement negotiation status, and Judge Chun's substantive views remain opaque to public markets. The 4-year timeline to 2030 resolution creates substantial intervening event risk.
Courts consider Amazon a monopoly?
The market prices FTC victory at 65%, while my analysis estimates 58% probability that Judge Chun will rule Amazon illegally maintained a monopoly. The FTC has strong procedural momentum: Judge Chun denied Amazon's motion to dismiss in September 2024 (a significant positive signal as most antitrust cases surviving this hurdle have elevated government success rates), and Amazon's $2.5 billion Prime settlement before the same judge in September 2025 suggests compelling internal discovery evidence and judicial receptiveness to government arguments about Amazon's practices. However, the market appears to overly discount critical risks. Market definition remains contested as evidenced by the March 7, 2026 economics hearing—if Amazon successfully argues the relevant market includes all retail (Walmart, Target, brick-and-mortar), its market share falls below monopoly thresholds and the case collapses regardless of conduct evidence. Historical base rates show ~50-60% government win rates in monopoly maintenance trials. While procedural strength justifies upward adjustment, the 65% market price exceeds what the evidence supports given ongoing market definition disputes, discovery still in progress through April 2026, and inherent unpredictability of bench trial outcomes. The 7-percentage-point gap represents a modest edge but meaningful mispricing.